Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $50.44 in the prior trading day, Cytokinetics Inc (NASDAQ: CYTK) closed at $50.40, down -0.08%. In other words, the price has decreased by -$0.08 from its previous closing price. On the day, 0.83 million shares were traded. CYTK stock price reached its highest trading level at $50.65 during the session, while it also had its lowest trading level at $49.73.
Ratios:
Our goal is to gain a better understanding of CYTK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.28 and its Current Ratio is at 9.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on November 08, 2024, initiated with a Outperform rating and assigned the stock a target price of $80.
On August 13, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $85 to $60.
UBS Downgraded its Buy to Neutral on January 24, 2024, whereas the target price for the stock was revised from $61 to $92.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 02 ’24 when Blum Robert I sold 5,000 shares for $50.76 per share. The transaction valued at 253,800 led to the insider holds 397,678 shares of the business.
ROBERT BLUM bought 5,000 shares of CYTK for $253,786 on Dec 02 ’24. On Nov 26 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 7,300 shares for $50.16 each. As a result, the insider received 366,181 and left with 111,878 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 5952643584 and an Enterprise Value of 5844451840. For the stock, the TTM Price-to-Sale (P/S) ratio is 1847.18. Its current Enterprise Value per Revenue stands at 1815.611 whereas that against EBITDA is -11.434.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $32.50. The 50-Day Moving Average of the stock is -5.04%, while the 200-Day Moving Average is calculated to be -13.61%.
Shares Statistics:
The stock has traded on average 1.22M shares per day over the past 3-months and 1286010 shares per day over the last 10 days, according to various share statistics. A total of 117.89M shares are outstanding, with a floating share count of 113.59M. Insiders hold about 3.74% of the company’s shares, while institutions hold 113.31% stake in the company. Shares short for CYTK as of 1731628800 were 14588795 with a Short Ratio of 11.97, compared to 1728950400 on 15537953. Therefore, it implies a Short% of Shares Outstanding of 14588795 and a Short% of Float of 18.86.
